Sativex Munnholsúði, lausn 27 mg/ml + 25 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sativex munnholsúði, lausn 27 mg/ml + 25 mg/ml

jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml

Vagidonna Leggangatafla 10 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vagidonna leggangatafla 10 míkróg

sandoz a/s* - estradiol - leggangatafla - 10 míkróg

Vagifem Leggangatafla 10 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vagifem leggangatafla 10 míkróg

novo nordisk a/s* - estradiolum inn - leggangatafla - 10 míkróg

Wellbutrin Retard Tafla með breyttan losunarhraða 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

wellbutrin retard tafla með breyttan losunarhraða 150 mg

glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 150 mg

Wellbutrin Retard Tafla með breyttan losunarhraða 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

wellbutrin retard tafla með breyttan losunarhraða 300 mg

glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg

Doloproct Endaþarmskrem 1 mg/g + 20 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

doloproct endaþarmskrem 1 mg/g + 20 mg/g

karo pharma ab* - lidocainum hýdróklóríð; fluocortolonum pívalat - endaþarmskrem - 1 mg/g + 20 mg/g

Doloproct Endaþarmsstíll 1 mg + 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

doloproct endaþarmsstíll 1 mg + 40 mg

karo pharma ab* - fluocortolonum pívalat; lidocainum hýdróklóríð - endaþarmsstíll - 1 mg + 40 mg

Rewellfem Leggangatafla 10 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rewellfem leggangatafla 10 míkróg

gedeon richter plc.* - estradiolum inn - leggangatafla - 10 míkróg

Adcetris Evrópusambandið - íslenska - EMA (European Medicines Agency)

adcetris

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - Æxlishemjandi lyf - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Advate Evrópusambandið - íslenska - EMA (European Medicines Agency)

advate

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). advate inniheldur ekki von willebrand þáttur í ly árangri magni og er því ekki fram í von willebrand sjúkdómur.